Latest News for: propionic
Edit
US Propionic Acid Prices Rise 4% as War Tensions and Feedstock Surge Drive Market Higher
Chem Analyst 18 Mar 2026
The upward movement followed a ...
Edit
Fluticasone Propionate Market Size to Reach USD 6.97 Billion by 2032 Driven by Rising Respiratory Disorders
Pharmiweb 13 Mar 2026
Edit
Citizen Tribune
04 Mar 2026
Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg ...
Citizen Tribune
04 Mar 2026
ELMWOOD PARK, N.J., March 4, 2026 /PRNewswire/ -- Glenmark Specialty SA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation ....
Edit
Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity
PR Newswire 04 Mar 2026
Edit
Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity (Glenmark Pharmaceuticals Limited)
Public Technologies 04 Mar 2026
Edit
US Calcium Propionate Prices Fall 3.9% in late February 2026, Subdued Demand Pressure Market
Chem Analyst 03 Mar 2026
Edit
Gettysburg Times
23 Feb 2026
Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for ...
Gettysburg Times
23 Feb 2026
... of clobetasol propionate ophthalmic suspension, ....
Edit
Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
PR Newswire 23 Feb 2026
APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT® nanoparticle formulation platform.
Edit
US Calcium Propionate Prices Decline 4.5% in early February 2026 Amid Supply Surplus
Chem Analyst 10 Feb 2026
Edit
Corsicana Daily Sun
30 Jan 2026
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
Corsicana Daily Sun
30 Jan 2026
Moderna will continue to lead clinical development and manufacturing for mRNA-3927 ....
Edit
Ample Supply and Soft Downstream Demand Keep US Propionic Acid Prices Low
Chem Analyst 30 Jan 2026
Edit
IR Insights: Recapping our Collaboration with Recordati to Globally Commercialize our Investigational Propionic Acidemia Therapy (Moderna Inc)
Public Technologies 29 Jan 2026
This is an abstract of the document. To keep reading, click here and get access to the original version. Attachments Original document Permalink. Disclaimer. Moderna Inc.
Edit
The Kane Republican
13 Jan 2026
Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate ...
The Kane Republican
13 Jan 2026
... the commercialization of clobetasol propionate ophthalmic ....
Edit
Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
PR Newswire 12 Jan 2026
APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT® nanoparticle formulation platform.
- 1
- 2
- Next page »